Creating a Global Company
Key Deals & Rationale
Deals
SUN
PHARMA
Year
Country
2022
Taro (Sun's subsidiary company) acquired
Alchemee Business from Galderma
US, Japan,
Canada
In-licensed WinleviⓇ
2021
US & Canada
(clascoterone cream 1%)
Exclusive licensing agreement with Himka
Middle East &
2020
for Ilumya
North Africa
2020
Licensing agreement with SPARC for
SCD-044
Global
Rationale
Acquired the "Proactiv", "Restorative Elements" and "In
Defense of Skin" brands. Strengthens Taro's OTC
portfolio
Topical treatment of acne vulgaris
Registration and commercialization of the product in
all Middle East & North Africa (MENA) markets.
Potential treatment for psoriasis, atopic dermatitis &
other
auto-immune disorders
2020
In-licensed Triferic brand from Rockwell
Medical Inc. (USA)
India
Expands nephrology portfolio in India - for treating
anaemia in hemodialysis patients.
2019
Licensing agreement with Astrazeneca UK
for ready-to-use infusion oncology products
Mainland
China
Access to oncology market in Mainland China
2019
Licensing agreement with CMS for
Tildrakizumab, Cequa & 8 generic products
Greater China
Access to Greater China market
2018
Acquired Pola Pharma in Japan
Japan
2016
Acquired global rights for Cequa & Odomzo
Global
Access to Japanese dermatology market.
Enhances specialty pipeline.
2016
Acquired Biosintez
Russia
Local manufacturing capability to enhance presence in
Russian market
2016
Licensing agreement with Almirall for
Tildrakizumab for Psoriasis
Europe
Access to European market for Tidrakizumab
16View entire presentation